Browse CCS

Summary
SymbolCCS
Namecopper chaperone for superoxide dismutase
Aliases superoxide dismutase copper chaperone
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF00403 Heavy-metal-associated domain
PF00080 Copper/zinc superoxide dismutase (SODC)
Function

Delivers copper to copper zinc superoxide dismutase (SOD1).

> Gene Ontology
 
Biological Process GO:0000041 transition metal ion transport
GO:0000302 response to reactive oxygen species
GO:0000303 response to superoxide
GO:0000305 response to oxygen radical
GO:0006801 superoxide metabolic process
GO:0006825 copper ion transport
GO:0006979 response to oxidative stress
GO:0009636 response to toxic substance
GO:0010035 response to inorganic substance
GO:0015680 intracellular copper ion transport
GO:0019430 removal of superoxide radicals
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0051341 regulation of oxidoreductase activity
GO:0051353 positive regulation of oxidoreductase activity
GO:0071450 cellular response to oxygen radical
GO:0071451 cellular response to superoxide
GO:0072593 reactive oxygen species metabolic process
GO:0098754 detoxification
GO:0098869 cellular oxidant detoxification
GO:1990748 cellular detoxification
Molecular Function GO:0004784 superoxide dismutase activity
GO:0005507 copper ion binding
GO:0008047 enzyme activator activity
GO:0015035 protein disulfide oxidoreductase activity
GO:0015036 disulfide oxidoreductase activity
GO:0016209 antioxidant activity
GO:0016530 metallochaperone activity
GO:0016531 copper chaperone activity
GO:0016532 superoxide dismutase copper chaperone activity
GO:0016667 oxidoreductase activity, acting on a sulfur group of donors
GO:0016721 oxidoreductase activity, acting on superoxide radicals as acceptor
GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005913 cell-cell adherens junction
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2262752: Cellular responses to stress
R-HSA-3299685: Detoxification of Reactive Oxygen Species
Summary
SymbolCCS
Namecopper chaperone for superoxide dismutase
Aliases superoxide dismutase copper chaperone
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CCS and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCCS
Namecopper chaperone for superoxide dismutase
Aliases superoxide dismutase copper chaperone
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CCS in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.70; FDR: 0.03680 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -1.99; FDR: 0.04220 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCCS
Namecopper chaperone for superoxide dismutase
Aliases superoxide dismutase copper chaperone
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CCS in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1250.675
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1310.954
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3090.856
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0330.914
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0420.982
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0190.994
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1330.688
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3080.797
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6730.628
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.020.991
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5860.822
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0220.725
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CCS in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCCS
Namecopper chaperone for superoxide dismutase
Aliases superoxide dismutase copper chaperone
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCS. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCCS
Namecopper chaperone for superoxide dismutase
Aliases superoxide dismutase copper chaperone
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCS. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCS.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCCS
Namecopper chaperone for superoxide dismutase
Aliases superoxide dismutase copper chaperone
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCS. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCCS
Namecopper chaperone for superoxide dismutase
Aliases superoxide dismutase copper chaperone
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CCS expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCCS
Namecopper chaperone for superoxide dismutase
Aliases superoxide dismutase copper chaperone
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CCS and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCCS
Namecopper chaperone for superoxide dismutase
Aliases superoxide dismutase copper chaperone
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CCS collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CCS.
ID Name Drug Type Targets #Targets
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119